Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abemaciclib in Advanced and Refractory GEP NETs
NCT03891784Phase 2Active, not recruiting
- Sponsor
- University of Washington
- Start
- Oct 2019
- Primary completion
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of abemaciclib in gastroenteropancreatic neuroendocrine tumor (GEP-NET), sponsored by University of Washington. Primary endpoint: Objective Response Rate up to 1 year. Started Oct 2019; status: active, not recruiting.
02
Drugs
abemaciclib
03
Conditions
gastroenteropancreatic neuroendocrine tumor (GEP-NET)
Beyond the preview
Go deeper on NCT03891784.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03891784.